Clinical Effect of Driver Mutations of KRAS, CDKN2A/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical Effect of Driver Mutations of KRAS, CDKN2A/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis

Published:2020-12-01 Issue:12 Volume:24 Page:777-788
ISSN:1945-0265
Container-title:Genetic Testing and Molecular Biomarkers
language:en
Short-container-title:Genetic Testing and Molecular Biomarkers

Author:

Gu Yujun¹,Ji Yayun²,Jiang Hui³,Qiu Ganbin³

Affiliation:

1. Department of Ultrasound Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou City, China.

2. Department of Interventional Ultrasound, Xianyang Central Hospital, Xianyang City, China.

3. Medical Imaging Department, Zhaoqing Medical College, Zhaoqing City, China.

Publisher

Mary Ann Liebert Inc

Subject

Genetics (clinical),General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/gtmb.2020.0078

Reference72 articles.

1. p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer

2. Notch1 Is Not Required for Acinar-to-Ductal Metaplasia in a Model of Kras-Induced Pancreatic Ductal Adenocarcinoma

3. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

4. DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma

5. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer;Frontiers in Oncology;2024-07-17

2. Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer;Current Issues in Molecular Biology;2024-03-23

3. Research insights into the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM): their roles in various tumors;PeerJ;2024-01-10

4. Recent advancement in molecular markers of pancreatic cancer;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

5. Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges;Seminars in Cancer Biology;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3